Zoetis Inc. (NYSE:ZTS) Position Decreased by Meeder Asset Management Inc

Alain Brian
Juillet 26, 2017

Assetmark Inc. boosted its stake in Zoetis by 4.6% in the first quarter. Jefferies maintained Zoetis Inc (NYSE:ZTS) rating on Tuesday, March 15. The firm purchased 483,714 shares of the company's stock, valued at approximately $25,816,000. Dimensional Fund Advisors LP owned approximately 0.27% of Zoetis worth $69,587,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the company. Assetmark Inc. now owns 1,918 shares of the company's stock worth $102,000 after buying an additional 85 shares in the last quarter. Fiduciary Trust Co. increased its position in shares of Zoetis by 59.4% in the first quarter. The Carnegie Capital Asset Management Llc holds 167,018 shares with $9.01 million value, up from 159,633 last quarter. First Interstate Bank increased its position in shares of Zoetis by 3.5% in the first quarter. New England Research & Management Inc. now owns 29,268 shares of the company's stock valued at $1,562,000 after buying an additional 10,523 shares during the period. Finally, Clearbridge Investments LLC boosted its stake in Zoetis by 4.2% in the first quarter. Raymond James Trust N.A. raised its stake in shares of Zoetis by 24.6% in the first quarter. Bokf Na holds 0.11% of its portfolio in Zoetis Inc (NYSE:ZTS) for 64,486 shares. On the other end, company shares have been noted 30.90% away from the low price over the last 52-weeks.

Dimensional Fund Advisors LP boosted its position in Zoetis Inc. Zoetis Inc. The stock has a market cap of $31.00 billion, a PE ratio of 36.51 and a beta of 1.03. (NYSE:ZTS) traded up 0.65% during mid-day trading on Friday, reaching $63.16. Marshall Wace Ltd Liability Partnership has 2.92% invested in Zoetis Inc (NYSE:ZTS). The stock's quarterly performance specifies a shift of 15.58%, and its last twelve month performance is stands at 33.83% while moved 7.62% for the past six months. The company generated a return on equity (ROE) of -4.80%. The company had revenue of $1.23 billion for the quarter, compared to analyst estimates of $1.20 billion. During the same quarter in the previous year, the firm earned $0.48 earnings per share. The firm's revenue for the quarter was up 5.9% compared to the same quarter a year ago. Equities research analysts predict that Zoetis Inc. will post $2.33 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 1st. Shareholders of record on Thursday, June 15th will be issued a $0.105 dividend. This represents a $0.42 dividend on an annualized basis and a dividend yield of 0.69%. The ex-dividend date is Tuesday, June 13th. Zoetis's dividend payout ratio (DPR) is now 24.42%.

TRADEMARK VIOLATION WARNING: This report was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this story on another site, it was stolen and republished in violation of US and global trademark & copyright law. The legal version of this report can be read at https://baseballnewssource.com/markets/next-financial-group-inc-buys-2314-shares-of-zoetis-inc-zts-updated/1196154.html. Barclays Capital maintained the stock with "Equal-Weight" rating in Thursday, August 4 report. Zacks Investment Research raised Zoetis from a "hold" rating to a "buy" rating and set a $71.00 price objective for the company in a research note on Tuesday, June 20th. They issued a "buy" rating and a $65.00 price objective on the stock. They set a "buy" rating and a $77.00 target price for the company. Finally, Deutsche Bank AG reissued a "buy" rating and issued a $65.00 target price (up previously from $62.00) on shares of Zoetis in a research note on Monday, July 17th. One research analyst has rated the stock with a sell rating, five have given a hold rating and thirteen have issued a buy rating to the company's stock. The firm has "Buy" rating given on Friday, May 26 by C.L. King.

In related news, insider Catherine A. Knupp sold 5,785 shares of the stock in a transaction on Friday, May 12th.

Here we'll take a quick glance at how the stock price is now trading in relation to some of its simple moving averages. The company had a trading volume of 6,067,931 shares. Following the sale, the insider now owns 24,415 shares of the company's stock, valued at $1,468,806.40.

Hologic, Inc.is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women's health.

Want to see what other hedge funds are holding ZTS? Company insiders own 0.31% of the company's stock.

D'autres rapports CampDesrEcrues

Discuter de cet article